Citius Oncology, Inc.
CTORNASDAQHealthcare● Active
$0.80
+$0.02(+2.55%)
Market Cap$74375662
P/E Ratio—
52W High$6.19
52W Low$0.491
Citius Oncology, Inc. (CTOR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CTOR · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.27
Est. -$0.01 · -2600.0%
Revenue
$0.00B
Est. $0.01B · -76.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
CTOR reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 18, 2026 | -$0.04 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.01 | -$0.27 | -2600.0% | $0.00B | $0.01B | -76.2% |
| ▼ Q1 FY2026 | Feb 13, 2026 | -$0.04 | -$0.06 | -50.0% | $0.00B | $0.00B | -9.8% |
| — Q4 FY2025 | Dec 23, 2025 | -$0.06 | -$0.06 | +0.0% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.15 | -$0.08 | +46.7% | — | — | — |
| ▼ Q2 FY2025 | May 14, 2025 | -$0.09 | -$0.11 | -22.2% | — | $0.01B | — |
| ▼ Q1 FY2025 | Feb 14, 2025 | -$0.06 | -$0.09 | -50.0% | — | — | — |
| ▲ Q4 FY2024 | Dec 27, 2024 | -$0.08 | -$0.07 | +10.3% | — | — | — |
Q3 FY2026
Aug 18, 2026
EPS Actual
—
EPS Est.
-$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.27
EPS Est.
-$0.01
EPS Surpr.
-2600.0%
Revenue
$0.00B
Q1 FY2026
Feb 13, 2026Miss
EPS Actual
-$0.06
EPS Est.
-$0.04
EPS Surpr.
-50.0%
Revenue
$0.00B
Q4 FY2025
Dec 23, 2025
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+0.0%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.08
EPS Est.
-$0.15
EPS Surpr.
+46.7%
Revenue
—
Q2 FY2025
May 14, 2025Miss
EPS Actual
-$0.11
EPS Est.
-$0.09
EPS Surpr.
-22.2%
Revenue
—
Q1 FY2025
Feb 14, 2025Miss
EPS Actual
-$0.09
EPS Est.
-$0.06
EPS Surpr.
-50.0%
Revenue
—
Q4 FY2024
Dec 27, 2024Beat
EPS Actual
-$0.07
EPS Est.
-$0.08
EPS Surpr.
+10.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2028 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2027 | $0.10 | $0.10 | $0.10 | 1 |
| Q2 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -2600.0% | $0.98 | $0.96 | -2.13% |
| ▼ Q1 FY2026 | Feb 13, 2026 | -50.0% | $1.18 | $1.22 | +3.39% |
| ▲ Q4 FY2025 | Dec 23, 2025 | +0.0% | $1.25 | $1.27 | +1.60% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +46.7% | $1.72 | $1.69 | -1.74% |
| ▼ Q2 FY2025 | May 14, 2025 | -22.2% | $0.92 | $0.89 | -2.83% |
| ▼ Q1 FY2025 | Feb 14, 2025 | -50.0% | $1.28 | $1.25 | -2.34% |
| ▲ Q4 FY2024 | Dec 27, 2024 | +10.3% | $0.96 | $1.04 | +8.33% |
| — Q1 FY2024 | Mar 31, 2024 | — | No price data | $11.43 | — |
Q2 FY2026-2.13%
Report Date
May 15, 2026
EPS Beat/Miss
-2600.0%
Price Before
$0.98
Price After
$0.96
Q1 FY2026+3.39%
Report Date
Feb 13, 2026
EPS Beat/Miss
-50.0%
Price Before
$1.18
Price After
$1.22
Q4 FY2025+1.60%
Report Date
Dec 23, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.25
Price After
$1.27
Q3 FY2025-1.74%
Report Date
Aug 12, 2025
EPS Beat/Miss
+46.7%
Price Before
$1.72
Price After
$1.69
Q2 FY2025-2.83%
Report Date
May 14, 2025
EPS Beat/Miss
-22.2%
Price Before
$0.92
Price After
$0.89
Q1 FY2025-2.34%
Report Date
Feb 14, 2025
EPS Beat/Miss
-50.0%
Price Before
$1.28
Price After
$1.25
Q4 FY2024+8.33%
Report Date
Dec 27, 2024
EPS Beat/Miss
+10.3%
Price Before
$0.96
Price After
$1.04
Q1 FY2024—
Report Date
Mar 31, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$11.43
Avg Beat Reaction+2.73%
Avg Miss Reaction-0.98%
Beat Rate3 / 8 quarters
Largest Move+8.33% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CTOR ends December
Citius Oncology, Inc. (CTOR) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.27 — missing the analyst consensus of $-0.01 by -2600.0%. The next CTOR earnings date is expected around September 1, 2026.
Each quarter, investors track CTOR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CTOR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CTOR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CTOR earnings · 5 questionsCitius Oncology, Inc.'s next earnings report is expected around September 1, 2026. CTOR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CTOR historically reports after market close (AMC).
CTOR earnings datewhen is CTOR earningsCTOR next earnings datewhen does CTOR report earningsCTOR earnings calendar
▸ Source: FMP · Citius Oncology, Inc. SEC filings · US GAAP · Citius Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026